We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. We are investing billions in Research and Development (R&D), which includes the discovery and development of new medicines.
Below is a list of our company's medicines. Any linked documents and websites are intended only for residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region.
Please refer to the patient leaflet information approved by the relevant governmental authority of the country where you are located and consult your physician for professional medical advice and services.
Adcortyl Intra-Articular/Intradermal Injection 10mg/ml
Amikin Injection 100MG/2ML
Azactam 1g or 2g Powder for Solution for Injection or Infusion
Baraclude 0.05 mg/ml oral solution
Baraclude 0.5 mg and 1.0 mg film coated tablets
Daklinza ▼ 30mg and 60mg film-coated tablets
Eliquis 2.5 mg film-coated tablets
Eliquis 5 mg film-coated tablets
Empliciti ▼ 300 mg and 400 mg powder for concentrate for solution for infusion
Etopophos 100mg Powder for Solution for Injection
Evotaz ▼ 300 mg/150 mg film-coated tablets
Fungizone 50mg Powder for Sterile Concentrate
Hydrea 500 mg Hard Capsules
Kenalog Intra-articular/Intramuscular Injection 40mg/ml
Nalorex 50mg Film-Coated Tablets
Nulojix 250 mg powder for concentrate for solution for infusion
Nystan 100,000 units/ml Oral Suspension (Ready-Mixed)
Opdivo ▼ 10 mg/mL concentrate for solution for infusion
Orencia 125 mg solution for injection (pre-filled syringe)
Orencia 125 mg solution for injection (pre-filled pen)
Orencia 250 mg powder for concentrate for solution for infusion
Perfalgan 10mg/ml Solution for Infusion
Questran Light 4g/sachet Powder for Oral Suspension
Questran 4g/sachet Powder for Oral Suspension
Reyataz, 150 mg, 200 mg and 300mg Hard Capsules
Sotacor 80mg Tablets
Sprycel 20mg, 50mg, 80mg, 100mg and 140mg Film Coated Tablets
Sustiva 50 mg, 100 mg and 200 mg Hard Capsules
Sustiva 600 mg Film-Coated Tablets
Vepesid Soft Capsules 50 mg and 100 mg
Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules
Yervoy 5 mg/ml concentrate for solution for infusion
Zerit 20 mg, 30 mg and 40 mg Hard Capsules
Zerit 200 mg Powder for Oral Solution
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or firstname.lastname@example.org
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or email@example.com
Risk Minimisation materials (e.g. educational brochures, patient alert cards, posters etc.) are intended to improve the use of a medicine by positively influencing health professionals and patients to reduce the risk and/or the severity of adverse reactions associated with a particular medicine.
These materials are additional to the medicine’s Summary of Product Characteristics (SmPC) and Patient Information Leaflet and their requirements are part of the product EU Risk Management Plan.
Only some medicines have a set of tailored risk minimisation materials developed for this purpose. If required, these materials are reviewed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA).
To access risk minimisation materials (where available electronically) for our medicines, please click on the link below to the electronic Medicines Compendium (eMC) website. Please note: after clicking link below you will then need to use the medicine search function to access a medicine's risk minimisation materials. After searching by medicine, click on the "Risk Materials" tab.
When you click on the hyperlink below you will be moving away from a BMS website to a website for which BMS has no responsibility.
If you would like a hard copy of a BMS medicine's risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 7311736, email: firstname.lastname@example.org) with your specific request.
Date of preparation: May 2018; MLTUK1701479-04